SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER
Sera Prognostics (NASDAQ: SERA) has appointed Lee Anderson as Chief Commercial Officer to lead its commercial expansion efforts. Anderson brings over 30 years of leadership experience in healthcare, particularly from his successful tenures at Genomic Health and Exact Sciences. His notable achievements include driving nine consecutive years of revenue growth as Vice President of US Oncology Sales and Global Customer Service at Genomic Health. Most recently, Anderson served as Chief Commercial Officer at Biofidelity Inc.
The appointment comes at a crucial time as Sera Prognostics enters its commercial phase following the successful PRIME study. Anderson will focus on expanding adoption and sales of the company's PreTRM Test, leveraging his extensive experience in the biotechnology and diagnostics sector.
Sera Prognostics (NASDAQ: SERA) ha nominato Lee Anderson come Chief Commercial Officer per guidare l'espansione commerciale dell'azienda. Anderson vanta oltre 30 anni di esperienza dirigenziale nel settore sanitario, con ruoli di successo presso Genomic Health ed Exact Sciences. Tra i suoi risultati più rilevanti, ha guidato nove anni consecutivi di crescita dei ricavi come Vicepresidente delle Vendite US Oncology e del Servizio Clienti Globale in Genomic Health. Più recentemente, Anderson è stato Chief Commercial Officer presso Biofidelity Inc.
La nomina arriva in un momento cruciale, mentre Sera Prognostics entra nella fase commerciale dopo il successo dello studio PRIME. Anderson si concentrerà sull'espansione dell'adozione e delle vendite del test PreTRM dell'azienda, sfruttando la sua vasta esperienza nel settore biotecnologico e diagnostico.
Sera Prognostics (NASDAQ: SERA) ha designado a Lee Anderson como Director Comercial para liderar la expansión comercial de la empresa. Anderson aporta más de 30 años de experiencia en liderazgo dentro del sector sanitario, destacando sus exitosos períodos en Genomic Health y Exact Sciences. Entre sus logros más importantes está haber impulsado nueve años consecutivos de crecimiento en ingresos como Vicepresidente de Ventas de Oncología en EE.UU. y Servicio al Cliente Global en Genomic Health. Recientemente, Anderson se desempeñó como Director Comercial en Biofidelity Inc.
El nombramiento se produce en un momento clave, ya que Sera Prognostics inicia su fase comercial tras el éxito del estudio PRIME. Anderson se enfocará en ampliar la adopción y las ventas del test PreTRM de la compañía, aprovechando su amplia experiencia en el sector biotecnológico y de diagnóstico.
Sera Prognostics (NASDAQ: SERA)는 상업 확장 노력을 이끌기 위해 Lee Anderson를 최고 상업 책임자(Chief Commercial Officer)로 임명했습니다. Anderson은 Genomic Health와 Exact Sciences에서의 성공적인 경력을 포함해 의료 분야에서 30년 이상의 리더십 경험을 보유하고 있습니다. 그는 Genomic Health에서 미국 종양학 영업 및 글로벌 고객 서비스 부사장으로서 9년 연속 매출 성장을 이끈 성과가 있습니다. 최근에는 Biofidelity Inc.에서 최고 상업 책임자로 근무했습니다.
이번 임명은 Sera Prognostics가 성공적인 PRIME 연구 이후 상업 단계에 진입하는 중요한 시점에 이루어졌습니다. Anderson은 생명공학 및 진단 분야에서의 폭넓은 경험을 바탕으로 회사의 PreTRM 테스트 채택 및 판매 확대에 집중할 예정입니다.
Sera Prognostics (NASDAQ: SERA) a nommé Lee Anderson au poste de Chief Commercial Officer afin de diriger ses efforts d'expansion commerciale. Anderson possède plus de 30 ans d'expérience en leadership dans le secteur de la santé, notamment grâce à ses réussites chez Genomic Health et Exact Sciences. Parmi ses réalisations notables, il a conduit neuf années consécutives de croissance des revenus en tant que Vice-Président des ventes oncologiques aux États-Unis et du service client mondial chez Genomic Health. Plus récemment, Anderson a occupé le poste de Chief Commercial Officer chez Biofidelity Inc.
Cette nomination intervient à un moment crucial alors que Sera Prognostics entre dans sa phase commerciale suite au succès de l'étude PRIME. Anderson se concentrera sur l'expansion de l'adoption et des ventes du test PreTRM de l'entreprise, en s'appuyant sur sa vaste expérience dans le secteur de la biotechnologie et du diagnostic.
Sera Prognostics (NASDAQ: SERA) hat Lee Anderson zum Chief Commercial Officer ernannt, um die kommerzielle Expansion des Unternehmens zu leiten. Anderson bringt über 30 Jahre Führungserfahrung im Gesundheitswesen mit, insbesondere durch seine erfolgreichen Tätigkeiten bei Genomic Health und Exact Sciences. Zu seinen bemerkenswerten Erfolgen zählt, dass er neun Jahre in Folge als Vice President für US Oncology Sales und Global Customer Service bei Genomic Health das Umsatzwachstum vorangetrieben hat. Zuletzt war Anderson Chief Commercial Officer bei Biofidelity Inc.
Die Ernennung erfolgt zu einem entscheidenden Zeitpunkt, da Sera Prognostics nach der erfolgreichen PRIME-Studie in die kommerzielle Phase eintritt. Anderson wird sich darauf konzentrieren, die Verbreitung und den Verkauf des PreTRM-Tests des Unternehmens auszubauen, wobei er seine umfangreiche Erfahrung im Biotechnologie- und Diagnosesektor nutzt.
- Appointment of highly experienced CCO with 30+ years of leadership in healthcare
- Strong track record of revenue growth (9 consecutive years) at previous companies
- Strategic timing of hire following successful PRIME study results
- Extensive experience in commercial strategy and product launches in diagnostics sector
- None.
Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company
"Lee is a highly accomplished leader with commercial expertise in fostering innovation, supporting continuous optimization and driving sales and offers a history of strong performance within the healthcare and diagnostics space," said Zhenya Lindgardt, President and CEO of Sera Prognostics. "With Sera now in the commercial phase following the strong results of our pivotal PRIME study, Lee will play a critical role in expanding adoption and sales of our PreTRM Test and we enthusiastically welcome Lee to our leadership team."
Mr. Anderson comes to Sera with a robust track record in leadership roles within the biotechnology and diagnostics sector, primarily highlighted by his transformative tenure at Genomic Health and Exact Sciences. At Genomic Health, which was later acquired by Exact Sciences, he escalated through various levels of increasing responsibility, finally spearheading US Oncology Sales and Global Customer Service as Vice President. Under his stewardship, he propelled the company into a leading product distributor in diagnostics, celebrating an impressive streak of nine consecutive years of revenue growth. His strategic acumen continued to thrive post-acquisition, where he excelled as the General Manager of Precision Oncology at Exact Sciences. Here, he was instrumental in driving nationwide sales growth and spearheading the launch of innovative new products.
Following his impactful tenure in these companies, Mr. Anderson held the role of Chief Commercial Officer at Biofidelity Inc. There, he leveraged his extensive experience to enhance their commercial strategy and significantly advance their market presence. Mr. Anderson holds a Bachelor of Science degree in Biology/Pre Medicine with a Minor in Chemistry from Florida State University, Tallahassee.
"I have been fortunate throughout my career to work for companies whose products were truly life changing," said Mr. Anderson. "Sera Prognostics is one of those companies. Together, this team will transform women's health care and positively impact the lives of mothers and their babies."
About Sera Prognostics, Inc.
Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera's mission is to provide early, pivotal pregnancy information to improve the health of mothers and newborns, resulting in reductions in the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera's precision medicine PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. Sera Prognostics is headquartered in
About Preterm Birth
Preterm birth is defined as any birth before 37 weeks' gestation and is the leading cause of illness and death in newborns. The 2024 March of Dimes Report Card shows that, for the last six consecutive years, more than one in ten infants is born prematurely in
About the PreTRM® Test
The PreTRM® Test is the only broadly validated, commercially available blood-based biomarker test that provides an early, accurate and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies. The PreTRM® Test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM® Test permits physicians to identify, during the weeks 18 through 20 of pregnancy, which women are at increased risk for preterm birth and its complications, enabling more informed, personalized clinical decisions based on each woman's individual risk. The PreTRM® Test is ordered by a medical professional.
Sera, Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States and/or other countries.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to expanding adoption and sales of our PreTRM test; long-term growth opportunities; the Company's ability to transform women's health care and positively impact the lives of mothers and their babies; ramping-up the Company's commercial strategy and developing market opportunities; and the Company's strategic directives under the caption "About Sera Prognostics, Inc." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: net losses, cash generation, and the potential need to raise more capital; revenues from the PreTRM Test representing substantially all Company revenues to date; the need for broad scientific and market acceptance of the PreTRM Test; a concentrated number of material customers; our ability to introduce new products; potential competition; our proprietary biobank; critical suppliers; estimates of total addressable market opportunity and forecasts of market growth; potential third-party payer coverage and reimbursement; new reimbursement methodologies applicable to the PreTRM Test, including new CPT codes and payment rates for those codes; changes in FDA regulation of laboratory-developed tests; the intellectual property rights protecting our tests and market position; and other factors discussed under the heading "Risk Factors" contained in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our periodic and current reports filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/sera-prognostics-appoints-lee-anderson-as-chief-commercial-officer-302450615.html
SOURCE Sera Prognostics, Inc.
FAQ
Who is the new Chief Commercial Officer of Sera Prognostics (SERA)?
What is Lee Anderson's previous experience before joining Sera Prognostics (SERA)?
Why did Sera Prognostics (SERA) appoint a new Chief Commercial Officer?
What will be Lee Anderson's main responsibilities at Sera Prognostics (SERA)?
